Clinical trial
Duloxetine Versus Placebo in the Treatment of FMS
NCT00233025 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00233025 |
|---|---|
| Title | Duloxetine Versus Placebo in the Treatment of FMS |
| Official title | Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibromyalgia |
| Intervention type | Drug |
| Interventions | Duloxetine, Placebo |
| Enrollment | 320 |
| Start date | Sep 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Oct 5, 2005 |
| Last update posted | Aug 23, 2007 |
| Countries | Germany, Puerto Rico, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: